COVID-19 mortality in patients after orthotopic heart transplantation: A single-center one-year observational study

The course and treatment of COVID-19 in heart transplant recipients: A case series from the late phase of the pandemic

“…Compared to a Silesian report from the early phase of the pandemic [5], we noticed lower mortality in our hospitalized cohort. The difference may reflect the declining trend in COVID-related mortality during the pandemic in solid organ transplant (SOT) recipients [8].…”

“…All patients were white men at the median (IQR) age of 52 (47-58) years. The median (IQR) time from HT to presentation was 5 (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17) months.…”

“…COVID-19, infectious severe acute respiratory syndrome caused by coronavirus 2 (SARS--CoV-2), has spread worldwide since December 2019, with varying intensity in different geographical regions and with diverse clinical presentations [1,2]. According to previous studies, heart transplant (HT) recipients are a particularly vulnerable population, with the COVID-19 mortality rate ranging from 24% to 43% in hospitalized patients [3][4][5]. Therefore, the COVID-19 course in this unique group still requires a better understanding to ensure a more effective medical treatment.…”